|
1.
|
|
20 p, 4.1 MB |
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer
/
Palafox, Marta (Hospital Universitari Vall d'Hebron) ;
Monserrat, Laia (Hospital Universitari Vall d'Hebron) ;
Bellet Ezquerra, Meritxell (Hospital Universitari Vall d'Hebron) ;
Villacampa Javierre, Guillermo (Hospital Universitari Vall d'Hebron) ;
Gonzalez-Perez, Abel (Universitat Pompeu Fabra) ;
Oliveira, Mafalda (Hospital Universitari Vall d'Hebron) ;
Brasó-Maristany, Fara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ibrahimi, Nusaibah (University Paris-Saclay) ;
Kannan, Srinivasaraghavan (Bioinformatics Institute (A*STAR)) ;
Mina, Leonardo (Medica Scientia Innovation Research (MedSIR)) ;
Herrera-Abreu, Maria Teresa (The Breast Cancer Now Research Centre) ;
Òdena, Andreu (Hospital Universitari Vall d'Hebron) ;
Sánchez-Guixé, Mònica (Hospital Universitari Vall d'Hebron) ;
Capelán, Marta (Hospital Universitari Vall d'Hebron) ;
Azaro, Analía (Hospital Universitari Vall d'Hebron) ;
Bruna, Alejandra (The Institute of Cancer Research (Londres)) ;
Rodríguez, Olga (Hospital Universitari Vall d'Hebron) ;
Guzmán, Marta (Hospital Universitari Vall d'Hebron) ;
Grueso, Judit (Hospital Universitari Vall d'Hebron) ;
Viaplana, Cristina (Hospital Universitari Vall d'Hebron) ;
Hernandez-Losa, Javier (Hospital Universitari Vall d'Hebron) ;
Su, Faye (Novartis Pharmaceuticals) ;
Lin, Kui (Genentech, Inc., South San Francisco) ;
Clarke, Robert B. (Manchester Breast Centre) ;
Caldas, Carlos (Cancer Research UK) ;
Arribas, Joaquín V (Hospital Universitari Vall d'Hebron) ;
Michiels, Stefan (University Paris-Saclay) ;
García-Sanz, Alicia (Medica Scientia Innovation Research (MedSIR)) ;
Turner, Nicholas C. (The Breast Cancer Now Research Centre) ;
Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ;
Nuciforo, Paolo (Hospital Universitari Vall d'Hebron) ;
Dienstmann, Rodrigo (Hospital Universitari Vall d'Hebron) ;
Verma, Chandra S. (National University of Singapore) ;
Lopez-Bigas, Nuria (Institució Catalana de Recerca i Estudis Avançats) ;
Scaltriti, Maurizio (Memorial Sloan-Kettering Cancer Center (Nova York, Estats Units d'Amèrica)) ;
Arnedos, Monica (Inserm Unit U981 (França)) ;
Saura, Cristina (Hospital Universitari Vall d'Hebron) ;
Serra, Violeta (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. [...]
2022 -  10.1038/s41467-022-32828-6
Nature communications, Vol. 13 (september 2022)
|
|
|
2.
|
|
1 p, 526.7 KB |
Author Correction : High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer
/
Palafox, Marta (Vall d'Hebron Institut d'Oncologia) ;
Monserrat, Laia (Vall d'Hebron Institut d'Oncologia) ;
Bellet Ezquerra, Meritxell (Hospital Universitari Vall d'Hebron) ;
Villacampa Javierre, Guillermo (Vall d'Hebron Institut d'Oncologia) ;
Gonzalez-Perez, Abel (Universitat Pompeu Fabra) ;
Oliveira, Mafalda (Hospital Universitari Vall d'Hebron) ;
Brasó-Maristany, Fara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ibrahimi, Nusaibah (University Paris-Saclay. Oncostat U1018, Inserm) ;
Kannan, Srinivasaraghavan (Bioinformatics Institute (A*STAR)) ;
Mina, Leonardo (Medica Scientia Innovation Research (MedSIR)) ;
Herrera-Abreu, Maria Teresa (The Breast Cancer Now Research Centre) ;
Òdena, Andreu (Vall d'Hebron Institut d'Oncologia) ;
Sánchez-Guixé, Mònica (Vall d'Hebron Institut d'Oncologia) ;
Capelán, Marta (Hospital Universitari Vall d'Hebron) ;
Azaro, Analía (Hospital Universitari Vall d'Hebron) ;
Bruna, Alejandra (The Institute of Cancer Research. Preclinical Modelling of Pediatric Cancer Evolution Group) ;
Rodríguez, Olga (Vall d'Hebron Institut d'Oncologia) ;
Guzmán, Marta (Vall d'Hebron Institut d'Oncologia) ;
Grueso, Judit (Vall d'Hebron Institut d'Oncologia) ;
Viaplana, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Hernandez-Losa, Javier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Su, Faye (Novartis Pharmaceuticals) ;
Lin, Kui (Genentech, Inc., South San Francisco) ;
Clarke, Robert B. (Manchester Breast Centre) ;
Caldas, Carlos (Cancer Research UK) ;
Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ;
Michiels, Stefan (University Paris-Saclay) ;
García-Sanz, Alicia (Medica Scientia Innovation Research (MedSIR)) ;
Turner, Nicholas C. (The Breast Cancer Now Research Centre) ;
Prat, Aleix (IOB Institute of Oncology (Barcelona, Catalunya)) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ;
Verma, Chandra S. (National University of Singapore. Department of Biological Sciences) ;
Lopez-Bigas, Nuria (Institució Catalana de Recerca i Estudis Avançats) ;
Scaltriti, Maurizio (Memorial Sloan-Kettering Cancer Center. Departments of Pathology and Human Oncology and Pathogenesis Program) ;
Arnedos, Monica (Inserm Unit U981) ;
Saura, Cristina (Hospital Universitari Vall d'Hebron) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
2022 - 10.1038/s41467-022-34580-3
Nature communications, Vol. 13 (november 2022)
|
|
|
3.
|
|
10 p, 1.3 MB |
Coamplification of miR-4728 protects HER2 -amplified breast cancers from targeted therapy
/
Floros, Konstantinos V. (Philips Institute for Oral Health Research) ;
Lochmann, Timothy L. (Philips Institute for Oral Health Research) ;
Hu, Bin (Virginia Commonwealth University School of Medicine) ;
Monterrubio, Carles (Memorial Sloan Kettering Cancer Center) ;
Hughes, Mark T. (Philips Institute for Oral Health Research) ;
Wells, Jason D. (Norris Cotton Cancer Center) ;
Bernadó Morales, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Ghotra, Maninderjit S. (Philips Institute for Oral Health Research) ;
Costa, Carlotta (Massachusetts General Hospital (Boston)) ;
Souers, Andrew J. (AbbVie Inc) ;
Boikos, Sosipatros A. (Virginia Commonwealth University) ;
Leverson, Joel D. (AbbVie Inc) ;
Tan, Ming (University of South Alabama) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ;
Koblinski, Jennifer E. (Virginia Commonwealth University School of Medicine) ;
Arribas, Joaquín V (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Paré Brunet, Laia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Miller, Todd W. (Norris Cotton Cancer Center) ;
Dozmorov, Mikhail G. (Virginia Commonwealth University) ;
Harada, Hisashi (Philips Institute for Oral Health Research) ;
Windle, Brad E. (Philips Institute for Oral Health Research) ;
Scaltriti, Maurizio (Memorial Sloan Kettering Cancer Center) ;
Faber, Anthony C. (Philips Institute for Oral Health Research)
In HER2 -amplified breast cancers, HER2 inhibitors have been very successful as adjuvant therapy but not as monotherapy. Here, we demonstrate that coamplification of a HER2 intronic miRNA causes intrinsic resistance to HER2 inhibitors by indirectly down-regulating the pro-apoptotic NOXA. [...]
2018 - 10.1073/pnas.1717820115
Proceedings of the National Academy of Sciences of the United States of America, Vol. 115 (february 2018) , p. E2594-E2603
|
|
|
4.
|
|
23 p, 4.1 MB |
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
/
Mateo, Lidia (Institute for Research in Biomedicine (IRB Barcelona)) ;
Duran-Frigola, Miquel (Institute for Research in Biomedicine (IRB Barcelona)) ;
Gris-Oliver, Albert (Vall d'Hebron Institut d'Oncologia) ;
Palafox, Marta (Vall d'Hebron Institut d'Oncologia) ;
Scaltriti, Maurizio (Memorial Sloan Kettering Cancer Center) ;
Razavi, Pedram (Memorial Sloan Kettering Cancer Center) ;
Chandarlapaty, Sarat (Memorial Sloan Kettering Cancer Center) ;
Arribas, Joaquín V (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Bellet Ezquerra, Meritxell (Vall d'Hebron Institut d'Oncologia) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ;
Aloy, Patrick (Institució Catalana de Recerca i Estudis Avançats)
Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) networks, and relate these to drug sensitivity. [...]
2020 - 10.1186/s13073-020-00774-x
Genome Medicine, Vol. 12 (september 2020)
|
|
|
5.
|
|
10 p, 1.9 MB |
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy
/
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Thyparambil, Sheeno (OncoPlex Diagnostics. USA) ;
Aura, Claudia (Vall d'Hebron Institut d'Oncologia) ;
Garrido-Castro, Ana (Hospital Universitari Vall d'Hebron) ;
Vilaro, Marta (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Jimenez, José (Vall d'Hebron Institut d'Oncologia) ;
Vicario, Rocío (Vall d'Hebron Institut d'Oncologia) ;
Cecchi, Fabiola (OncoPlex Diagnostics. USA) ;
Hoos, William (OncoPlex Diagnostics. USA) ;
Burrows, Jon (OncoPlex Diagnostics. USA) ;
Hembrough, Todd (OncoPlex Diagnostics. USA) ;
Ferreres Piñas, Joan Carles (Hospital Universitari Vall d'Hebron) ;
Pérez-Garcia, José (Hospital Universitari Vall d'Hebron) ;
Arribas, Joaquín V. (Vicente) (Institució Catalana de Recerca i Estudis Avançats) ;
Cortés, Javier (Hospital Universitari Vall d'Hebron) ;
Scaltriti, Maurizio (Memorial Sloan Kettering Cancer Center) ;
Universitat Autònoma de Barcelona
Introduction: Current methods to determine HER2 (human epidermal growth factor receptor 2) status are affected by reproducibility issues and do not reliably predict benefit from anti-HER2 therapy. Quantitative measurement of HER2 may more accurately identify breast cancer (BC) patients who will respond to anti-HER2 treatments. [...]
2016 - 10.1016/j.molonc.2015.09.002
Molecular Oncology, Vol. 10, núm 1 (January 2016) , p. 138-147
|
|
|
6.
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
